Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

International Stem Cell Corp. (ISCO) Also Develops Advanced Stem Cell Technology for Skin-Deep Results

A leader in regenerative medicine, International Stem Cell Corp. uses its parthenogenesis stem cell technology to address immune rejection and self-renewing cells. This technology uses unfertilized eggs that have cells with a duplicate set of human leukocyte antigen genes (HLA) that lessen the chance of a body rejecting cells. From this, scientists created self-renewing human […]

Giggles N’ Hugs, Inc. (GIGL) Winning Family-Friendly Restaurant Concept/Execution Driving Nationwide, International Mall Receptivity

Taking kids under 10 out to a nice casual dining restaurant is an experience most parents dread. No matter how well-behaved a child may be, the setting is typically unnatural for kids, and the child’s instincts to play are generally and uniformly suppressed, resulting in an uncomfortable experience for all. This sad reality makes what […]

ROI Land Investments Ltd. (ROII) is “One to Watch”

With recently reported U.S. housing starts markedly higher in September, above one million for the sixth month in a row and beating the estimates of 1.15 million by analysts at Reuters handedly, U.S. Economic Outlook data forecasting 16 percent growth through Q4 2016 appears well within reason. In the country’s biggest home construction markets down […]

Elephant Talk Communications Corp. (ETAK) Says Voice Biometrics is Best

The recent fingerprint hacking of over five million United States government employees raises questions about the safety of biometrics. Biometrics, a technology that measures and analyzes biological data like voice, fingerprint, iris, and facial scans, is used by companies like Apple and Samsung to unlock user-specific products. However, rising concerns over biometric use within customer-based […]

Dominovas Energy Corp. (DNRG) Announces Landmark Financing Commitment for $1.2 Billion US Dollars

Dominovas Energy, a leading power solutions provider to emerging markets around the world, issued a press release today announcing a landmark capital commitment for $1.2 billion US Dollars in project financing (the “Financing”) with Graecrest Energy Solutions. The funds will be used for the initial phase to manufacture, produce, and deploy Dominovas Energy’s proprietary RUBICON™ […]

OurPet’s Company (OPCO) Continues to Grow Presence in the Pet Products Marketplace by Introducing New Products

OurPet’s Company develops, produces and markets various accessories and consumable pet products designed to awaken pets’ natural instincts. Sold globally, the company’s products are marketed under the brand names – OurPets® for the Pet Specialty channel, Pet Zone® for food, drug and mass chains and Petastic® for the value channel. The Company’s sub-brands Play-N-Squeak™, Cosmic […]

QualityStocks Features Legacy Ventures International, Inc. (LGYV) CEO in Exclusive Interview

QualityStocks today announces the availability of a new audio interview with Evan Clifford, CEO of Legacy Ventures International, Inc., an investment company highly focused on high-potential businesses with “big idea” and game-changing innovations. The interview can be heard at http://www.QualityStocks.net/interview-lgyv.php. The interview kicks off as Clifford explains Legacy’s recent acquisition of Canada-based RM Fresh Brands, […]

 

From Our Blog

Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics

December 15, 2025

The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates fall to just 3%. These economics have created a bottleneck that leaves patients waiting years for […]

Rotate your device 90° to view site.